IndraLab

Statements


5 54 32 | 2 2 13 5

reach
"Glycogen synthase becomes phosphorylated at Ser644 in response to osmotic shock; this phosphorylation is prevented by pretreatment of the cells with SB 203580, which inhibits SAPK2a and p38a and SAPK2b and p38b activity."

No evidence text available

reach
"It is not blocked by SB 203580, which inhibits SAPK2a and p38alpha and SAPK2b and p38beta but not SAPK3 and p38gamma, or by the ERK pathway inhibitor PD 184352."

sparser
"P38α and p38β are inhibited by SB 203580 and SB 202190, with IC 50 s of 0.092 μM and 1 μM, respectively."

No evidence text available

No evidence text available

sparser
"Inhibition of p38alpha by the specific inhibitor SB 203580 prevented activation-induced cell death in T cells."

reach
"The observation that overexpression of wild-type S6K in HEK293 cells increases the IC 50 10-fold from that of endogenous S6K in fibroblasts raises the possibility that Ro 31-6045 also targets the inac[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

"Our data set represents the most detailed comprehensive assessment of the reactivity of known and clinical kinase inhibitors across the kinome published to date. | The data also show that for at least 15 of the 27 kinases that are the primary, intended targets for the compounds tested and that are represented in the assay panel, selective inhibitors, as assessed by both absolute selectivity across the kinome and selectivity relative to the primary target, are among the 72 tested here."

reach
"SB203580 has been well characterized to inhibit the SAPK2a and 2b isoforms of p38 by> = 90% without appreciably (< 30%) affecting related kinases such as ERK (extracellular signal regulated kinase) or JNK (c-Jun N-terminal kinase), or 17 other widely expressed kinases."

eidos
"Therefore , we speculate that inhibition of MAPK14 by SB203580 may reduce the levels of CREB1 and ARC ."

reach
"PD 98059 prevents the activation of MAP kinase kinase-1 [12], the enzyme that activates the MAP kinase family members MAPK1 and ERK1 and MAPK2 and ERK2 in the ` classical ' MAP kinase cascade, while S[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

reach
"XREF_BIBR In addition, inhibition of MAPK14 by SB203580 has previously been associated with autophagic cell death as characterized by the accumulation of large cytosolic vacuoles."

"Pretreatment of hela cells with sb 203580, a pyridinyl imidazole compound that specifically inhibits p38 mitogen-activated protein kinase (mapk). It has previously been established that sb 203580 acts primarily to block the catalytic activity of p38 mapk. However, it has been suggested that in cells, the compounds could also inhibit p38 mapk activation by virtue of their ability to bind to the inactive enzyme."

No evidence text available

reach
"Conversely, the inhibition of MAPK14 by SB203580 and the down-regulation of MAP2K3 and MAP2K6 (kinases upstream of MAPK14) by specific siRNA did not alter the activation of MAPK3/1."

sparser
"SB 203580 inhibits p38α, β and β2 (not γ and δ) MAP kinase by competing with the substrate ATP [ xref , xref ]."

sparser
"Unlike SAPK1 (also called JNK), SAPK3 and SAPK4 did not phosphorylate the activation domain of c-Jun. Unlike SAPK2a and SAPK2b, SAPK4 and SAPK3 were not inhibited by the drugs SB 203580 and SB 202190."

"Pretreatment of hela cells with sb 203580, a pyridinyl imidazole compound that specifically inhibits p38 mitogen-activated protein kinase (mapk). It has previously been established that sb 203580 acts primarily to block the catalytic activity of p38 mapk. However, it has been suggested that in cells, the compounds could also inhibit p38 mapk activation by virtue of their ability to bind to the inactive enzyme."

reach
"SB203580 is a competitive inhibitor of p38alpha and p38beta by blocking ATP binding to the kinase, while BIRB796 is an allosteric inhibitor of p38alpha, p38beta, and p38gamma."

reach
"SB203580, a pyridinyl imidazole which inhibits SAPK2a [34], has been widely used to implicate this signalling pathway in the phosphorylation of eIF4E [2,3,5,16,18-21,28]."

reach
"SB203580 has been used to inhibit MAPK14 and p38-alpha and MAPK11 and p38-beta with IC 50 = 50 nM and 500 nM respectively XREF_BIBR, XREF_BIBR."

reach
"The compound SB203580 specifically inhibits p38 and CSBP kinase activities, whereas PD098059 selectively blocks activation of the ERK kinase MEK1, which in turn prevents activation of ERK1/2."

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

trips
"Although CA treatment decreased the phosphorylation of p38 mitogen‑activated protein (MAP) kinase and p53, p38 MAP kinase inhibition by SB203580 did not affect SM‑induced cell death."

No evidence text available

trips
"This p38 MAP kinase, like p38 alpha, is inhibited by the pyridinyl imidazole drug SB203580."

No evidence text available

No evidence text available

No evidence text available

No evidence text available

eidos
"Interestingly , inhibition of MAPK14 activity by SB203580 and SB202190 also decreased the number of SNX27-positive puncta and increased their average size ( Fig. 4 F ) ."

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

sparser
"Moreover, the pyridinyl-imidazole compounds SB 203580 and SB 202190 inhibit SAPK2a and SAPK2b, but not SAPK3 and SAPK4 ."

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

"Pretreatment of hela cells with sb 203580, a pyridinyl imidazole compound that specifically inhibits p38 mitogen-activated protein kinase (mapk). It has previously been established that sb 203580 acts primarily to block the catalytic activity of p38 mapk. However, it has been suggested that in cells, the compounds could also inhibit p38 mapk activation by virtue of their ability to bind to the inactive enzyme."

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

reach
"Moreover, the pyridinyl-imidazole compounds SB 203580 and SB 202190 [41] inhibit SAPK2a and SAPK2b, but not SAPK3 and SAPK4 [24]."

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available
| DOI

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

No evidence text available

reach
"Phosphorylation was not prevented by SB 203580 (an inhibitor of SAPK2a and p38alpha and SAPK2b and p38beta2) and/or PD 184352 (which inhibits the activation of ERK1 and ERK2), and was similar in fibroblasts lacking both SAPK3 and p38gamma and SAPK4 and p38delta or JNK1 and JNK2."

"Pretreatment of hela cells with sb 203580, a pyridinyl imidazole compound that specifically inhibits p38 mitogen-activated protein kinase (mapk). It has previously been established that sb 203580 acts primarily to block the catalytic activity of p38 mapk. However, it has been suggested that in cells, the compounds could also inhibit p38 mapk activation by virtue of their ability to bind to the inactive enzyme."